You missed the point. The point is p2 tests under Dr. M are exploratory, so yes the data requires deep analysis including genomic analysis, which takes a long time. For the P3 tests, the targets are defined, so the data analysis is easier and it is obvious what we will look at.
Whether 273 works for alz is a different issue. It either works or it doesn't. That is what we have to determine.
The alz trial was originally set up as an Australia only trial, with EU, Canada arms set up later. So doing an analysis of the Australian data should be a straightforward matter. And it might enable the TGA to provide accelerated approval.
Gee, I get whacked from your side for even asking for a look, and Kund's side for thinking we can get a look in a timely manner. I guess than means I have the median, optimal opinion.
News 
Market Data 
Discover 
